Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks to Participate in Upcoming Investor Conferences and Events

Business Wire February 10, 2021

Zymeworks Expands Commercial Team and Creates New R&D Role

Business Wire February 9, 2021

Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development

Business Wire January 27, 2021

Zanidatamab Data Highlight Durable Antitumor Activity in HER2?Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium

Business Wire January 15, 2021

Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities

Business Wire January 11, 2021

Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49

Business Wire January 7, 2021

Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Business Wire December 10, 2020

Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

Business Wire December 2, 2020

Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGene

Business Wire December 1, 2020

Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer

Business Wire November 30, 2020

Unmet Medical Need: Millions of Americans Could Benefit from Next-Generation NSAIDs

Livemoney November 24, 2020

Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer

Business Wire November 19, 2020

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2?Expressing Breast Cancer

Business Wire November 16, 2020

Zymeworks to Present at Upcoming Investor Conferences

Business Wire November 10, 2020

Zymeworks Reports 2020 Third Quarter Financial Results

Business Wire November 3, 2020

Zymeworks to Present at Upcoming Investor Conferences

Business Wire September 3, 2020

Zymeworks Reports 2020 Second Quarter Financial Results

Business Wire August 5, 2020

Zymeworks Corporate Update Webcast and Conference Call Summary

Business Wire July 8, 2020

Zymeworks Announces New Multispecific Antibody Collaboration with Merck

Business Wire July 8, 2020

Zymeworks Announces Corporate Update Webcast and Conference Call

Business Wire June 30, 2020